The potential effects of safranal on rotenone-induced Parkinson’s disease (PD) have been evaluated in an in vitro study in which, safranal decreased cellular apoptosis, ROS generation and expression of kelch-like-ECH-associated protein-1 (keap1) by promoting nuclear translocation of Nrf2. Here, NFE2L2 is linked to Parkinson disease.